Cantitate/Preț
Produs
Total produse
Vezi coșul
New Targets for the Treatment of Hypertension and Associated Diseases de William B. Campbell

New Targets for the Treatment of Hypertension and Associated Diseases: Advances in Pharmacology, cartea 94

William B. Campbell, John D. Imig
en Limba Engleză Hardback – 6 iun 2022
New Targets for the Treatment of Hypertension and Associated Diseases, Volume 94 in the Advances in Pharmacology serial, highlights new advances in the field, with this new volume presenting interesting chapters on Cytochrome P450, 20-hydroxyeicosatetraenoic acid and GPR75 pathway in hypertension, Treatment of hypertension with soluble epoxide hydrolase inhibitors, Effects of allosteric modifiers of adenosine receptors in the heart, Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury, Drugs affecting the nitric oxide- cyclic GMP pathway in hypertension, Relaxin-2 and Serelaxin in renal and cardiac dysfunction in hypertension, and more.

  • Provides the authority and expertise of leading contributors from an international board of authors
  • Presents the latest release in Advances in Pharmacology series
  • Updated release includes the latest information on New Targets for the Treatment of Hypertension and Associated Diseases
Citește tot Restrânge

Din seria Advances in Pharmacology

Preț: 107105 lei

Preț vechi: 143016 lei
-25% Nou

Puncte Express: 1607
Preț estimativ în valută:
20501€ • 21496$ • 16939£

Carte tipărită la comandă

Livrare economică 22 ianuarie-05 februarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780323910873
ISBN-10: 0323910874
Pagini: 420
Dimensiuni: 152 x 229 mm
Greutate: 0.73 kg
Editura: ELSEVIER SCIENCE
Seria Advances in Pharmacology

Public țintă

Academic, government and industrial sectors.

Cuprins

1. The CYP/20-HETE/GPR75 axis in hypertension Ghezal Froogh, Victor Garcia and Michal L. Schwartzman 2. Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury John D Imig 3. Pharmacological developments in antihypertensive treatment through nitric oxide-cGMP modulation Annika A. Jüttner, A.H. Jan Danser and Anton J.M. Roks 4. Sphingosine-1-phosphate and sphingosine-1-phosphate receptors in the cardiovascular system: Pharmacology and clinical implications Simona Federica Spampinato, Maria Angela Sortino and Salvatore Salomone 5. Polymorphisms in common antihypertensive targets: Pharmacogenomic implications for the treatment of cardiovascular disease Dominique Brown, Heather Alcala, Peter Oelschlaeger and Bradley T. Andresen 6. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension Prasad Chunduri, Shrey A. Patel and Scott P. Levick 7. Cardiovascular effects of GLP-1 receptor agonism Raymond J. Winquist and Valentin K. Gribkoff 8. ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease HaiFeng Yang and Raouf A. Khalil 9. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology Giorgio Minotti, Pierantonio Menna, Massimiliano Camilli, Emanuela Salvatorelli and Roberto Levi